Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Early Phase 1

1(20.0%)

Phase 2

1(20.0%)

Phase 3

1(20.0%)

N/A

1(20.0%)

Phase 4

1(20.0%)

5Total

Early Phase 1(1)

Phase 2(1)

Phase 3(1)

N/A(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT02460107Early Phase 1Terminated

Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy

Role: lead

NCT02490293Not ApplicableCompleted

Is it Fair to Use Antibiotics After Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder?

Role: collaborator

NCT01518998Phase 2Completed

A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension

Role: collaborator

NCT01658020Phase 3Completed

A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg

Role: collaborator

NCT01579500Phase 4Completed

Neuropathic Pain Study With Botulinum Toxin A in Spinal Cord Injury Patients

Role: lead

All 5 trials loaded